| 注册
首页|期刊导航|中德临床肿瘤学杂志(英文版)|培美曲塞治疗晚期非小细胞肺癌近期疗效分析

培美曲塞治疗晚期非小细胞肺癌近期疗效分析

Yongfa Zheng Wei Ge Ling Zhang Zhenyu Zhao Fangfang Jie

中德临床肿瘤学杂志(英文版)2011,Vol.10Issue(3):140-143,4.
中德临床肿瘤学杂志(英文版)2011,Vol.10Issue(3):140-143,4.DOI:10.1007/s10330-011-0757-z

培美曲塞治疗晚期非小细胞肺癌近期疗效分析

Clinical observation of pemetrexed on advanced non-small-cell lung cancer

Yongfa Zheng 1Wei Ge 1Ling Zhang 1Zhenyu Zhao 1Fangfang Jie1

作者信息

  • 1. Department of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China
  • 折叠

摘要

Abstract

Objective: The aim of our study was to observe the efficacy and toxicity of 50 cases of advanced non-small cell lung cancer (NSCLC) patients treated by pemetrexed. Methods: Fifty patients, including 29 females and 21 males, with a median age 62 years (35-82 years), 13 of whom were treated with pemetrexed only and the left 37 cases were treated with pemetrexed combined with platinum in the Department of Oncology, Renmin Hospital of Wuhan University from June 2006 to March 2009. Single agent regimen: patients received pemetrexed 500 mg/m2 on day 1 with every 21 days. Combination regimen: patients received pemetrexed 500 mg/m2 on day 1 and carboplatin 300 mg/m2 on day 1 or cisplatin 35 mg/m2 on day 1 to day 3 or nedaplatin 80 mg/m2 on day 1 by intravenous infusion with 21 days as one cycle. RECIST 1.0 standard was used to evaluate the clinical efficiency, and the WHO toxicity standard was used to evaluate toxic reaction, and the QOL was used to evaluate the quality of life. Results: All patients were given 162 cycles (at least 2 cycles, at most 6 cycles) and the response rate of all the patients were evaluated. There were 2 complete remission (CR), 7 partial remission (PR), 22 stable disease (SD) and 19 progressive disease (PD) in the group, the overall response rate was (RR) was 18.0% and disease control rate (DCR) 62.0%. The quality of life improvement rate reaches 58.0%. The major toxic reaction included neutropenia,thrombocytopenia, hypemia, nausea, and vomiting. Most of the severity of these effects was grade I-II and well tolerated.Conclusion: Chemotherapy with pemetrexed or pemetrexed combined with platinum in the treatment of advanced non-small cell lung cancer is effective, safe and well-tolerable, which can improve quality of life of the patient.

关键词

non-small-cell lung cancer/ pemetrexed/ chemotherapy

Key words

non-small-cell lung cancer/ pemetrexed/ chemotherapy

引用本文复制引用

Yongfa Zheng,Wei Ge,Ling Zhang,Zhenyu Zhao,Fangfang Jie..培美曲塞治疗晚期非小细胞肺癌近期疗效分析[J].中德临床肿瘤学杂志(英文版),2011,10(3):140-143,4.

中德临床肿瘤学杂志(英文版)

OACSTPCD

2095-9621

访问量0
|
下载量0
段落导航相关论文